The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Annals of Oncology

• Publication date

  2016-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdw623PMID 28426105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.

  2015cited by this paper
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  2014cited by this paper
• The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

  2014cited by this paper
• FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast

  2013cited by this paper
• An international Ki67 reproducibility study.

  2013influential reference
• Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

  2013cited by this paper
• Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype

  2013cited by this paper
• A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

  2013cited by this paper
• Relationship between the Inflammatory Molecular Profile of Breast Carcinomas and Distant Metastasis Development

  2012cited by this paper
• CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

  2012cited by this paper
• Impact of CD68/(CD3+CD20) Ratio at the Invasive Front of Primary Tumors on Distant Metastasis Development in Breast Cancer

  2012cited by this paper
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cited by this paper
• Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

  2010cited by this paper
• Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

  2010cited by this paper
• Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.

  2010cited by this paper
• Autoantibodies in breast cancer: their use as an aid to early diagnosis.

  2007cited by this paper
• Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

  2007cited by this paper
• Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

  2006cited by this paper
• Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors

  2005cited by this paper

• Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression

  2025cites this paper
• Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights

  2025influential citation
• Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS

  2025cites this paper
• Spatial evaluation and prognostic significance of VISTA in human resectable cervical carcinoma: Implications for immune activation and suppression.

  2025cites this paper
• Tumor infiltration therapy: from FDA approval to next-generation approaches

  2025cites this paper
• Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives

  2025cites this paper
• B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses

  2025cites this paper
• The Microenvironment in DCIS and Its Role in Disease Progression.

  2025cites this paper
• A prognostic and predictive computational pathology immune signature for ductal carcinoma in situ: retrospective results from a cohort within the UK/ANZ DCIS trial

  2024cites this paper
• From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment

  2024cites this paper
• Thematic trends and knowledge-map of tumor-infiltrating lymphocytes in breast cancer: a scientometric analysis

  2024cites this paper
• Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast

  2024cites this paper
• Stromal lymphocytes are associated with upgrade of B3 breast lesions

  2024cites this paper
• Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes

  2024cites this paper
• Research Progress on the Relationship between Tumor Infiltrating Lymphocytes and Prognosis of Different Molecular Types of Breast Cancer

  2024cites this paper
• Immune cell infiltrate in ductal carcinoma in situ and the risk of dying from breast cancer: case–control study

  2024cites this paper
• Tumor microenvironmental determinants of high-risk DCIS progression

  2024cites this paper
• Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.

  2024cites this paper
• Everybody needs good neighbours: the progressive DCIS microenvironment.

  2023cites this paper
• The Biology and Management of Ductal Carcinoma in Situ of the Breast.

  2023cites this paper
• Combining the guidelines and multiphoton imaging methods to improve the prognostic value of tumor‐infiltrating lymphocytes in breast cancer

  2023cites this paper
• Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer

  2023cites this paper
• Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast

  2022influential citation
• The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ

  2022cites this paper
• Study the effect of isolated human epidermal growth factor receptor (HER2) from plasma on histopathological aspects in some organs of adult female albino rats

  2022cites this paper
• Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast

  2022cites this paper
• The clinical significance of HER2 expression in DCIS

  2022cites this paper
• Learning to distinguish progressive and non-progressive ductal carcinoma in situ

  2022cites this paper
• Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors.

  2022cites this paper
• Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast

  2022cites this paper
• Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology

  2022cites this paper
• Immunologic determinants of mammary tumors: PD-L1 and TILS

  2022cites this paper
• Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk

  2022cites this paper
• Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression

  2022cites this paper
• Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2

  2022cites this paper
• Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ

  2022cites this paper
• Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.

  2022cites this paper
• Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ

  2021influential citation
• Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence

  2021cites this paper
• Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer

  2021cites this paper
• The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ

  2021cites this paper
• Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

  2021cites this paper
• Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer.

  2021cites this paper
• The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.

  2021cites this paper
• Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells

  2021cites this paper
• Pathological Aspects for Diagnosis

  2021cites this paper
• Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis

  2021cites this paper
• The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer

  2021cites this paper
• Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent

  2020cites this paper
• The Immune Landscape in Women Cancers.

  2020cites this paper
• Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast

  2020cites this paper
• The prognostic significance of immune microenvironment in breast ductal carcinoma in situ

  2020influential citation
• Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors

  2020cites this paper
• Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis

  2020cites this paper
• Ductal Carcinoma In Situ—Pathological Considerations

  2020cites this paper
• Tumour‐infiltrating lymphocytes in ductal carcinoma in situ (DCIS)—assessment with three different methodologies and correlation with Oncotype DX DCIS Score

  2020influential citation
• The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.

  2020cites this paper
• Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ

  2020influential citation
• Upregulation of HIF1-α via an NF-κB/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli

  2020influential citation
• High EZH2 expression in ductal carcinoma in situ diagnosed on breast core needle biopsy is an independent predictive factor for upgrade on surgical excision.

  2020cites this paper
• The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.

  2019cites this paper
• Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer

  2019cites this paper
• Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy.

  2019cites this paper
• Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer.

  2019cites this paper
• Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies

  2019cites this paper
• Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ.

  2019cites this paper
• Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.

  2019cites this paper
• Higher densities of tumour‐infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast

  2019influential citation
• The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting

  2019cites this paper
• Associations of B7-H3 and B7-H4 Expression in Ductal Carcinoma In Situ of the Breast With Clinicopathologic Features and T-Cell Infiltration

  2019cites this paper
• Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

  2019cites this paper
• Ductal carcinoma in situ of the breast: immune cell composition according to subtype

  2019cites this paper
• Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS)

  2019cites this paper
• Prognostic role of immune infiltrates in breast ductal carcinoma in situ

  2019cites this paper
• Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses

  2019cites this paper
• A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast

  2019cites this paper
• Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy

  2018cites this paper
• Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast

  2018influential citation
• Prognostic Significance of Tumour Infiltrating Lymphocytes in Ductal Carcinoma in Situ of the Breast

  2018influential citation
• Possible predictive role of cancer/testis antigens in breast ductal carcinoma in situ

  2018cites this paper
• Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance

  2018cites this paper
• Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality

  2018cites this paper
• Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

  2018cites this paper
• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

  2017cites this paper
• Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis

  2017cites this paper
• Breast cancer genomics and immuno-oncological markers to guide immune therapies.

  2017cites this paper
• Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.

  2017cites this paper
• Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features

  2017cites this paper
• Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

  2017cites this paper
• Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?

  2017influential citation
• Biomarkers in ductal carcinoma in situ

  2016cites this paper